UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Promising therapeutic targets in neuroblastoma

Clinical cancer research, 2012-05, Vol.18 (10), p.2740-2753

2012

Volltextzugriff (PDF)

I-Metaiodobenzylguanidine Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications

Seminars in nuclear medicine, 2016-05, Vol.46 (3), p.184-202

2016

Volltextzugriff (PDF)

Targeted radionuclide therapy in combined-modality regimens

The lancet oncology, 2017-07, Vol.18 (7), p.e414-e423

2017

Volltextzugriff (PDF)

(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis

Clinical endocrinology (Oxford), 2014-04, Vol.80 (4), p.487-501

2014

Volltextzugriff (PDF)

Reaching the target dose with one single 131 I-mIBG administration in high-risk neuroblastoma: The determinant impact of the primary tumour

Pediatric blood & cancer, 2024-03, Vol.71 (3), p.e30806-e30806

2024

Volltextzugriff (PDF)

Radioiodinated Metaiodobenzylguanidine (MIBG): Radiochemistry, Biology, and Pharmacology

Seminars in nuclear medicine, 2011-09, Vol.41 (5), p.324-333

2011

Volltextzugriff (PDF)

A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study

Pediatric blood & cancer, 2021-10, Vol.68 (10), p.e29117

2021

Volltextzugriff (PDF)

MIBG in Neuroblastoma Diagnostic Imaging and Therapy

Radiographics, 2016-01, Vol.36 (1), p.258-278

2016

Volltextzugriff (PDF)

Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient

The journal of clinical endocrinology and metabolism, 2024-08, Vol.109 (9), p.2366-2388

2024

Volltextzugriff (PDF)

Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma

Seminars in nuclear medicine, 2023-07, Vol.53 (4), p.517-529

2023

Volltextzugriff (PDF)

I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma

Seminars in nuclear medicine, 2016-05, Vol.46 (3), p.203-214

2016

Volltextzugriff (PDF)

Peptide Receptor Radionuclide Treatment and (131)I‐MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas

Journal of surgical oncology, 2017-03, Vol.115 (4), p.425-434

2017

Volltextzugriff (PDF)

Too many targets, not enough patients: rethinking neuroblastoma clinical trials

Nature reviews. Cancer, 2018-06, Vol.18 (6), p.389-400

2018

Volltextzugriff (PDF)

Intrasubject relationship between striatal 18F-FP-CIT uptake and cardiac 123I-MIBG uptake differs by motor subtype in early Parkinson disease

Medicine (Baltimore), 2021-08, Vol.100 (33), p.e26995-e26995

2021

Volltextzugriff (PDF)

Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma

Journal of Nuclear Medicine, 2021-09, Vol.62 (9), p.1192-1199

2021

Volltextzugriff (PDF)

Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG

The journal of clinical endocrinology and metabolism, 2020-03, Vol.105 (3), p.e494-e501

2020

Volltextzugriff (PDF)

Addition of 131 I-MIBG to PRRT ( 90 Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

Journal of Nuclear Medicine, 2021-09, Vol.62 (9), p.1274-1277

2021

Volltextzugriff (PDF)

Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma

Pediatric blood & cancer, 2024-01, Vol.71 (1), p.e30743-e30743

2024

Volltextzugriff (PDF)

Neuroblastoma: Therapeutic strategies for a clinical enigma

Cancer treatment reviews, 2010-06, Vol.36 (4), p.307-317

2010

Volltextzugriff (PDF)

Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma

Current treatment options in oncology, 2020-08, Vol.21 (11), p.85-85, Article 85

2020

Volltextzugriff (PDF)

Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma

Seminars in nuclear medicine, 2023-07, Vol.53 (4), p.503-516

2023

Volltextzugriff (PDF)

Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis

Annals of nuclear medicine, 2024-07, Vol.38 (7), p.553-562

2024

Volltextzugriff (PDF)

Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

Cancer, 2022-11, Vol.128 (21), p.3775-3783

2022

Volltextzugriff (PDF)

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours

Endocrine-related cancer, 2011-10, Vol.18 (S1), p.S27-S51

2011

Volltextzugriff (PDF)

1 – 25 von 784

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(627)
Mit Volltextzugriff
(504)

Publikationsform

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(763)
3-Iodobenzylguanidine
(429)
Female
(407)
Male
(405)
Science & Technology
(351)
Life Sciences & Biomedicine
(350)
Iodine Radioisotopes - Therapeutic Use
(335)
3-Iodobenzylguanidine - Therapeutic Use
(320)
Adult
(250)
Radionuclide Imaging
(240)
Iodobenzenes - Therapeutic Use
(233)
Child
(226)
Middle Aged
(224)
Neuroblastoma - Radiotherapy
(197)
Antineoplastic Agents - Therapeutic Use
(188)
Biological And Medical Sciences
(182)
Child, Preschool
(180)
Medical Sciences
(176)
Radiopharmaceuticals - Therapeutic Use
(164)
Aged
(150)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Promising therapeutic targets in neuroblastoma

I-Metaiodobenzylguanidine Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications

Targeted radionuclide therapy in combined-modality regimens

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis

Reaching the target dose with one single 131 I-mIBG administration in high-risk neuroblastoma: The determinant impact of the primary tumour

Radioiodinated Metaiodobenzylguanidine (MIBG): Radiochemistry, Biology, and Pharmacology

A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study

MIBG in Neuroblastoma Diagnostic Imaging and Therapy

Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient

Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma

I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma

Peptide Receptor Radionuclide Treatment and (131)I‐MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas

Too many targets, not enough patients: rethinking neuroblastoma clinical trials

Intrasubject relationship between striatal 18F-FP-CIT uptake and cardiac 123I-MIBG uptake differs by motor subtype in early Parkinson disease

Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma

Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG

Addition of 131 I-MIBG to PRRT ( 90 Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma

Neuroblastoma: Therapeutic strategies for a clinical enigma

Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma

Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma

Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis

Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours

Suchergebnisse filtern